<DOC>
	<DOC>NCT02291029</DOC>
	<brief_summary>This study will evaluate the safety,tolerability and preliminary therapeutic efficacy of multiple doses of intravenous infusion of CFZ533 monoclonal antibody in patients with primary Sjögren's syndrome(pSS)</brief_summary>
	<brief_title>Safety, Pharmacokinetics and Preliminary Efficacy Study of CFZ533 in Patients With Primary Sjögren's Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Sjogren's Syndrome</mesh_term>
	<criteria>Diagnosis of primary Sjögren's syndrome ESSDAI score ≥ 6 Secondary Sjögren's syndrome Receiving cyclosphosphamide, corticosteroid bolus with dose over 1 mg/kg, rituximab, belimunab, other immunosuppressives. At significant risk for thromboembolic event Clinically significant systemic infection Significant elevated risk for infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Sjögren's syndrome, CFZ533, ESSDAI</keyword>
</DOC>